Ozoralizumab |
| Catalog No.GC72440 |
Ozoralizumab (ATN-103) es un anticuerpo anti-TNFα humanizado.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1167985-17-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Ozoralizumab (ATN-103; 0-1000 pM; 48 h) has high TNFα-neutralizing potency in the L929 cell cytotoxicity assay with KD values of 20.2 pM and 16.1 pM for human TNFα and monkey TNFα, respectively[1].
Ozoralizumab (ATN-103; 1 mg/kg; s.c.; Tg197 human TNF transgenic mice) inhibits arthritis and reduces arthritis scores[1].
References:
[1]. Ishiwatari-Ogata C, et, al. Ozoralizumab, a Humanized Anti-TNFα NANOBODY® Compound, Exhibits Efficacy Not Only at the Onset of Arthritis in a Human TNF Transgenic Mouse but Also During Secondary Failure of Administration of an Anti-TNFα IgG. Front Immunol. 2022 Feb 22;13:853008.
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *